Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: An open-label, randomized, parallel-group study

Epilepsia

Volumn 45, Issue 9, 2004, Pages 1049-1053

  Coppola, Giangennaro ^a   Auricchio, Gianfranca ^a   Federico, Rosario ^a   Carotenuto, Marco ^a   Pascotto, Antonio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Lamotrigine; Monotherapy; Typical absences; Valproic acid

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ABSENCE; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HYPERVENTILATION; MALE; PRIORITY JOURNAL; RANDOMIZATION; RECORDING; SEIZURE; SIDE EFFECT; STROBOSCOPY;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MONITORING, AMBULATORY; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 4544220589     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.40903.x     Document Type: Article

References (23)

1. Callaghan N, O'Hare J, Driscoll D, et al. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982;24:830-6.
2. Sato S, White BG, Penry JK, et al. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982;32:157-63.
3. Zahn CA, Morrell MJ, Collins SD, et al. Management issues for women with epilepsy: a review of the literature. Neurology 1998;51:949-56.
4. Browne TR, Dreifuss FE, Dyken PR, et al. Ethosuximide in the treatment of absence (petit mal) seizures. Neurology 1975;25:515-24.
5. Blomquist HK, Zetterlund B. Evaluation of treatment in typical absence seizures: the roles of long-term EEG monitoring and ethosuximide. Acta Paediatr Scand 1985;74:409-15.
6. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
7. Ferrie CD, Robinson RO, Knott C, et al. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 1995;91:200-2.
8. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol 1997;12(suppl 1):S29-37.
9. Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-9.
10. Gericke CA, Picard F, de Saint-Martin A, et al. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. Epileptic Disord 1999;1:159-65.
11. Buoni S, Grosso S, Fois A. Lamotrigine in typical absence epilepsy. Brain Dev 1999;21:303-6.
12. Barron TF, Hunt SL, Hoban TF, et al. Lamotrigine monotherapy in children. Pediatr Neurol 2000;23:160-3.
13. Janszky J, Rasonyi G, Halasz P, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level: report of two cases. Clin Neuropharmacol 2000;23:86-9.
14. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91.
15. Panayiotopoulos CP. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 2001;3:379-403.
16. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
17. Perucca E. Pharmacological and therapeutic properties of valproate. CNS Drugs 2002;16:695-714.
18. Davis R, Peters DH. McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-72.
19. Villareal HJ, Wilder BJ, Willmore LJ, et al. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978;28:886-91.
20. Braathen G, Theorell K, Persson A, et al. Valproate in the treatment of absence epilepsy in children: a study of dose-response relationships. Epilepsia 1988;29:548-52.
21. Genton P, Bauer J, Duncan S, et al. On the association between valproate and polycystic ovary syndrome. Epilepsia 2001;42:295-304.
22. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992;42(suppl 5):149-60.
23. Lerman-Sagie T, Watemberg N, Kramer U, et al. Absence seizures aggravated by valproic acid. Epilepsia 2001;42:941-3.